Conclusion
With the increase in pediatric transplants and more evidence revealing EBV SMT are not as benign in the pediatric population as previously thought, further investigations to understand the immune system with focus on the pediatric transplant population is warranted15. At present, the treatment for EBV SMT in the pediatric population remains individualized with varying reported successes1,3. With the limited number of current cases, a multi-center approach assessing current therapeutic approaches and their efficacies is needed to create a more standardized approach to the treatment of EBV SMT.